Orthofix Medical Inc. Common Stock (DE)

Day range

$9.65 – $9.83

Open

$9.65

Prev close

$9.81

Volume

200.6K

Market cap

$399.59M

Shares out

40.73M

P/E

—

P/S

0.48

P/B

0.93

P/FCF

—

ROE

-14.4%

ROA

-7.1%

Debt/Equity

0.55

Div yield

0.00%

As of Oct 23, 2026

• Investor presentationAug 5, 2026

  The Company expects to use the corporate investor relations presentation furnished as Exhibit 99.2 to this report, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts, and others during the fiscal year ending December 31, 2026.

• Regulatory decisionJul 2, 2026

  On April 16, 2026, the U.S. Food and Drug Administration ('FDA') issued a final order reclassifying non-invasive bone growth stimulators from Class III to Class II devices.

• Annual meeting resultsJun 11, 2026

  On June 10, 2026, the Company held the Annual Meeting. At the Annual Meeting: 1. Election of Board of Directors. The following persons were elected as directors of the Company for a one-year term expiring at the 2027 Annual Meeting of Shareholders: [10 directors listed with voting results]. 2. Advisory and Non-Binding Resolution to Approve Executive Compensation was approved by a vote of (i) 24,480,474 in favor, (ii) 5,577,200 against, and (iii) 14,545 abstaining. 3. Ratification of the Selection of Ernst & Young LLP was ratified by a vote of (i) 33,262,505 in favor, (ii) 1,384,292 against, and (iii) 129,879 abstaining. 4. Approval of Amendment No. 5 to the Company's Second Amended and Restated Stock Purchase Plan by a vote of (i) 29,235,005 in favor, (ii) 831,625 against, and (iii) 5,589 abstaining.

• Guidance withdrawalMay 21, 2026

  In light of these developments, the Company's three-year financial targets are no longer applicable.

• Executive officer departureApr 9, 2026

  On April 9, 2026, the Company announced that Max Reinhardt, the Company's President, Global Spine, will be departing as an executive and employee on or about June 12, 2026. The Company expects that Mr. Reinhardt's departure will be treated under his change in control and severance agreement with the Company as either a termination of employment without Cause, or resignation for Good Reason, during a Non-CIC Period, and that he will be entitled to receive the payments and benefits provided for thereunder.

• MMSIMerit Medical Systems Inc+0.96%

Days to cover

5.5

Short interest

2.44M

Avg volume

444.81K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Orthobiologics Market to Surpass USD 9 Billion by 2031 Amid Rising Osteoarthritis Cases and Advancements in Regenerative Therapies, Says Mordor Intelligence
  positiveGlobeNewswire Inc.· Mar 12, 2026
• Orthofix (OFIX) Q2 Revenue Rises 2%
  positiveThe Motley Fool· Aug 5, 2025
• Intramedullary Nail Market size to worth USD 1,537 Million by 2032, says Coherent Market Insights
  positiveGlobeNewswire Inc.· Apr 10, 2025
• Prosthetic Disc Nucleus Market Outlook to Exceed US$ 265.8 Million by 2034, Driven by Minimally Invasive Surgery Innovations | Latest Report by Transparency Market Research Inc.
  positiveGlobeNewswire Inc.· Feb 28, 2025
• OFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
  negativeGlobeNewswire Inc.· Nov 8, 2024